NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/10/2026 15:52
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6,078.58 mln
Float173 mln
Earnings Date11/10/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
55.82
Transformational upside
Relative Strength
22
/ 100
Significantly lagging
Debt / Equity
0.46
Low leverage
ROE
-84.42
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Cogent Biosciences is a clinical-stage company working to develop targeted treatments for patients with specific genetic mutations that drive serious diseases. Its most advanced drug, bezuclastinib, is currently in Phase 3 testing and aims to treat conditions such as systemic mastocytosis and certain gastrointestinal tumors by blocking the faulty protein signals that cause them. The company also has several earlier-stage drugs in development targeting other genetic abnormalities found in cancers including bile duct cancer and solid tumors. Based in Waltham, Massachusetts, Cogent operates under a licensing agreement with Plexxikon Inc. covering the development and commercialization of its lead treatment.
